2007年7月
Midkine as a novel target for antibody therapy in osteosarcoma
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- 巻
- 358
- 号
- 3
- 開始ページ
- 757
- 終了ページ
- 762
- 記述言語
- 英語
- 掲載種別
- DOI
- 10.1016/j.bbrc.2007.04.183
- 出版者・発行元
- ACADEMIC PRESS INC ELSEVIER SCIENCE
Osteosarcoma is a malignant tumor with poor prognosis, and lack of accurate prognostic factors is one of the reasons that make this tumor difficult to cure. The heparin-binding growth factor, midkine is involved in generation and progression of many types of tumors. However, the relationship between midkine and osteosarcoma has been unclear. We show here that midkine is overexpressed in osteosarcoma and the level of midkine expression is correlated with prognosis (P < 0.05; log-rank test). Treatment with functional antibodies against midkine suppresses growth of osteosarcoma cell lines, 9N2, 3N1, Saos-2, and NOS-1, to 25-65% of untreated controls. Our results suggest that midkine is useful as a prognostic marker, and is a candidate therapeutic target for osetosarcomas. (c) 2007 Elsevier Inc. All rights reserved.
- リンク情報
- ID情報
-
- DOI : 10.1016/j.bbrc.2007.04.183
- ISSN : 0006-291X
- Web of Science ID : WOS:000247124900015